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Background. Amyotrophic lateral sclerosis (ALS) is a fatal, progressive neurodegenerative disease characterized by rapid loss
of muscle control and eventual paralysis due to the death of large motor neurons in the brain and spinal cord. Growth factors
such as glial cell line derived neurotrophic factor (GDNF) are known to protect motor neurons from damage in a range of
models. However, penetrance through the blood brain barrier and delivery to the spinal cord remains a serious challenge.
Although there may be a primary dysfunction in the motor neuron itself, there is also increasing evidence that excitotoxicity
due to glial dysfunction plays a crucial role in disease progression. Clearly it would be of great interest if wild type glial cells
could ameliorate motor neuron loss in these models, perhaps in combination with the release of growth factors such as GDNF.
Methodology/Principal Findings. Human neural progenitor cells can be expanded in culture for long periods and survive
transplantation into the adult rodent central nervous system, in some cases making large numbers of GFAP positive astrocytes.
They can also be genetically modified to release GDNF (hNPC
GDNF) and thus act as long-term ‘mini pumps’ in specific regions of
the rodent and primate brain. In the current study we genetically modified human neural stem cells to release GDNF and
transplanted them into the spinal cord of rats over-expressing mutant SOD1 (SOD1
G93A). Following unilateral transplantation
into the spinal cord of SOD1
G93A rats there was robust cellular migration into degenerating areas, efficient delivery of GDNF
and remarkable preservation of motor neurons at early and end stages of the disease within chimeric regions. The progenitors
retained immature markers, and those not secreting GDNF had no effect on motor neuron survival. Interestingly, this robust
motor neuron survival was not accompanied by continued innervation of muscle end plates and thus resulted in no
improvement in ipsilateral limb use. Conclusions/Significance. The potential to maintain dying motor neurons by delivering
GDNF using neural progenitor cells represents a novel and powerful treatment strategy for ALS. While this approach
represents a unique way to prevent motor neuron loss, our data also suggest that additional strategies may also be required
for maintenance of neuromuscular connections and full functional recovery. However, simply maintaining motor neurons in
patients would be the first step of a therapeutic advance for this devastating and incurable disease, while future strategies
focus on the maintenance of the neuromuscular junction.
Citation: Suzuki M, McHugh J, Tork C, Shelley B, Klein SM, et al (2007) GDNF Secreting Human Neural Progenitor Cells Protect Dying Motor Neurons,
but Not Their Projection to Muscle, in a Rat Model of Familial ALS. PLoS ONE 2(8): e689. doi:10.1371/journal.pone.0000689
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a fatal, progressive neurode-
generative disease characterized by rapid loss of muscle control and
eventual paralysis due to the death of large motor neurons in the
spinal cord and brainstem [1,2]. The cause of sporadic ALS remains
unclear. However, in a small group of familial ALS (FALS) patients,
a clear genetic link to point mutations in superoxide dismutase 1
(SOD1) has been shown [3]. This has led to the generation of
transgenic mice and rats over-expressing multiple copies of mutant
SOD1 (SOD1
G93A) that have many of the characteristics of both the
familial and sporadic form of human disease [4,5].
Motor neuron death in ALS is a complex process, and may
involve multiple pathways including formation of protein aggre-
gates, axonal transport defects, oxidative damage, mitochondrial
defects, and alterations in calcium homeostasis [6]. Healthy motor
neurons express components of glial cell line derived neurotrophic
factor (GDNF) receptors and can bind, internalize and transport
the protein in both retro- and anterograde directions [7,8]. Many
studies have shown that GDNF protects motor neurons from
degeneration in vitro [9]. However, delivery of GDNF in vivo has
been hindered by limited bio-availability, inability of this protein
to cross the blood-brain barrier or penetrate gray matter, and by
a relatively short half-life. Gene therapy approaches using
adenoviral vectors encoding GDNF or cells releasing GDNF have
shown that muscle delivery of this factor and subsequent
retrograde transport to motor neurons in the spinal cord can be
effective in slowing degeneration in the mouse SOD 1 mutant [10–
12]. However, retrograde transport may be affected early in the
disease [13] and larger animals such as rats and monkeys may be
less efficient at taking back the protein to the spinal cord thus
limiting this approach in patients. Only one study has attempted
direct delivery of GDNF to the motor neurons of the SOD1
G93A
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result in lumbar motor neuron protection, although there was
some modest protection of facial motor neurons [14]. Further-
more, recent evidence from transgenic mice suggests that direct
expression of GDNF by astrocytes within the spinal cord does not
result in motor neuron protection when compared to muscle
delivery [15]. However, in both of these studies, sick astrocytes
and/or neurons carrying the SOD1 mutation were forced to
release GDNF which may have compromised the effectiveness of
this approach.
Although there may be a primary dysfunction in the motor
neuron itself, there is also increasing evidence that excitotoxicity
due to astrocyte dysfunction and inflammatory processes from
microglia activation play a crucial role in disease progression
[2,4,16–18]. Most of the studies to date have focused on
modulating the ratio of mutant SOD1 over expression and
normal cells in transgenic mice and have shown that reducing the
number of glia expressing the mutation can have a significant
impact on motor neuron survival and disease progression [17–20].
While of great interest, these studies did not assess whether adding
wild type glial cells into an environment where every cell carries
the mutation would have a similar effect, or whether growth
factors may further ameliorate motor neuron death. Results from
this experiment would have clear clinical implications for patients
with the disease.
Human neural progenitor cells (hNPC) can be expanded in
culture for long periods and survive transplantation into the adult
rodent central nervous system, in some cases making large numbers
of GFAP positive astrocytes at longer survival times [21–26]. These
cells can also be genetically modified to release GDNF
(hNPC
GDNF) and thus act as long-term ‘mini pumps’ in specific
regions of the rodent and primate brain [27]. We have also shown
that hNPC
GDNF can survive transplantation into the lumbar spinal
cord of the SOD1
G93A rat and continue to release GDNF within
this degenerative environment [28]. In the current study we show
that delivery of GDNF by these cells has a remarkable protective
effect on motor neuron cell death in highly chimeric regions of the
SOD1
G93A rat spinal cord, even at disease end point. This was not
through modulation of the host glial response, or up regulation of
glutamate transporters such as glutamate transporter-1 (GLT1)
around the surviving motor neurons. Surprisingly, these surviving
motor neurons did not appear to maintain their contact with
muscle and there were no improvements in ipsilateral hind limb
function. The potential to maintain dying motor neurons with
GDNF in this severe degenerative model points to possible novel
stem cell treatment strategies for ALS.
METHODS
Animals
Breeder SOD1
G93A rats, which had been originally generated by
Howland et al. [5], were obtained from Taconic (http://www.
taconic.com/), and colonies were developed by crossing male
founders with female Taconic Sprague Dawley rats (http://www.
taconic.com/). We began breeding the SOD1
G93A rat colony from
founder animals and found a constant but predictable drift in
disease onset and duration in addition to a gender specific effect
with males being more severely affected than females [29]. This is
entirely consistent with the pattern of familial ALS in humans
[1,2]. We used two different cohorts of rats and the variation with
regard to disease onset and progression in our hSOD1
G93A rats
was observed as previously described [29]. Heterozygous
SOD1
G93A progeny were identified with polymerase chain
reaction (PCR) of tail DNA with primers specific for hSOD1.
They were maintained in a room with controlled illumination
(lights on 0500–1900 h) and temperature (2361uC), and given free
access to laboratory chow and tap water. Rats were considered
end-stage (endpoint) when they no longer exhibited reflexes
allowing them to right themselves within 30 seconds. Body weight
measurement and all behavioral testing began at an age of 65 days
and continued until endpoint. All the animal procedures in the
present study were carried out in accordance with the guidelines
for University of Wisconsin-Madison and National Institutes of
Health standards of animal care.
Cell culture
Human fetal tissue (between 10 and 15 weeks of conception) was
obtained from the Birth Defects Laboratory at the University of
Washington. The method of collection conformed to the guidelines
recommended by National Institutes of Health for the collection of
such tissues and set out by the University of Washington and the
University of Wisconsin, Madison. Institutional Review board
approval was obtained for all of these studies. Human cortical
neural progenitor/stem cells (M031 line) were prepared from fetal
brains and induced to proliferate as neurospheres using established
passaging methods to achieve optimal cellular expansion as
previously described in detail [24]. Freshly dissected fetal tissue
was dissociated in 0.1% trypsin and seeded into T75 flasks at
a density of 200,000 cells per ml of maintenance medium
[Dulbecco’s modified Eagle medium (DMEM)/Ham’s F12 (7:3)
containing penicillin/streptomycin/amphotericin B (PSA, 1% v/v)]
supplemented with B27 (2% v/v; Invitrogen, http://probes.invitro-
gen.com/), EGF (20 ng/ml; Sigma-Aldrich, http://www.sigmaal-
drich.com/), and fibroblast growth factor-2 (FGF-2; 20 ng/ml;
R&D Systems, http://www.rndsystems.com/) with heparin (5 mg/
ml; Sigma). Neurosphere colonies rapidly formed and were passaged
every 14 days by sectioning neurospheres into 200 mmu s i n ga n
automated tissue chopper as described previously [24]. At 2 weeks
after the first passage, the cells were switched to maintenance
medium containing N2 supplement (1%; Invitrogen) and 20 ng/ml
EGF. After 10 weeks of growth, 10 ng/ml LIF (Chemicon, http://
www.chemicon.com/) was added to enhance expansion rates.
Lentiviral infection
We used a viral construct for constitutive expression of GDNF
under the control of the mouse phosphoglycerate kinase 1 (PGK1)
promoter (Figure 1). Posttranslational cis-acting regulatory ele-
ment of the woodchuck hepatitis virus (WHV) is included and has
been shown to significantly enhance transgene expression. The
lenti-GDNF inactivated virus was produced as described pre-
viously [30]. High-titer stocks were obtained by ultracentrifuga-
tion, and the lentiviral particles were suspended in 1% bovine
serum albumin in phosphate buffered saline. Particle content of
viral batches was determined by p24 antigen ELISA (PerkinElmer
Life Sciences, http://las.perkinelmer.com/). hNPC cultures were
gently dissociated with Accutase (Innovative Cell Technologies,
http://www.innovativecelltech.com/) to single cell suspension,
washed extensively, counted and diluted to 1,000 cells/mli n
culture medium. The cells were mixed with virus at a titer of
100 ng/p24/million cells and allowed to reform spheres in a 24
well plate. We could maintain this production for up to 20 weeks
of expansion in culture [31]. For GDNF immunohistochemistry,
some spheres were dissociated in a single cell suspension with
Accutase for 10 min at 37uC. The resulting cells (25,000 cells/
50 ml) were plated to glass coverslips coated with poly-L-lysine and
laminin (Sigma-Aldrich) and cultured in the plating medium
[maintenance medium with 2% B27 supplement (Invitrogen)] for
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maintained and differentiated for 7 days under serum-free
conditions [26]. The concentrations of GDNF protein in the
conditioned medium were measured by enzyme-immunoassays
(human GDNF DuoSet, R&D systems).
Cell transplantation
Long-term culture (10 weeks) of lenti-GDNF (hNPC
GDNF) or wild-
type (hNPC
WT) human cortical neuropsheres were dissociated to
single cells using Accutase and resuspended in the transplantation
medium (49% Leibovitz L-15/49% PBS-glucose/2% B27 supple-
Figure 1. Modification of human neural progenitor cells to release GDNF by lentiviral infection. (A) Schematic illustration of GDNF expressing
hNPC preparation. Naı ¨ve neural progenitor cells (hNPC
WT) were infected with lentivirus to produce GDNF (hNPC
GDNF). (B) Schematic illustration of
lentivirus construct. LTR, long terminal repeat; PGK, mouse phosphoglycerate kinase 1 promotor; WPRE, post transcriptional regulatory element of
woodchuck hepatitis virus; cPPT, central polypurine tract; SIN, self-inactivating. Photomicrographs of hNPC
WT (C) and hNPC
GDNF (D) show robust
expression of GDNF protein (E). Approximately 87% of cells were shown to express GDNF. (F) hGDNF protein was detected by ELISA in the culture
medium after lentivirus infection. (G) GDNF expressing hNPC did not down-regulate the transgene after differentiation, but rather accumulated it in
the media over time. Scale bar: 20 mm.
doi:10.1371/journal.pone.0000689.g001
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on ice. SOD1
G93A rats were anesthetized with isoflurane and the
lumbar vertebrae were exposed and clamped in a spinal
stereotaxic frame (David Kopf Instruments, http://www.kopfin-
struments.com/) to maintain a steady position. Injection holes
were drilled in laminae within L1 and L4 spinal cord segments,
and the spinal cord was exposed. Cell suspension (120–180,000
cells in 1–2 ml, 4 sites per rat) was unilaterally injected 1.8 mm
ventral from the dorsal dura surface at L1–4 using a 10 ml
Hamilton syringe outfitted with a 75–100 mm tipped micropipette
[28,32]. Cyclosporine (i.p. 10 mg/kg, Novartis, http://www.
novartis.com/) was administered daily beginning 3 days before
surgery and until sacrifice.
Immunohistochemistry
The animals were transcardially perfused with chilled 0.9% saline
and 4% paraformaldehyde-phosphate buffered saline, and the
spinal cords were collected. For neuromuscular junction analysis,
tibialis anterior muscles of some animals were removed prior to
fixation. Spinal cords were cryoprotected in 30% sucrose, and the
lumbar regions were sectioned in 35 or 50 mm using a cryostat.
One in six sections were processed for Nissl staining or
immunostanined for human nuclei (hNUC, mouse monoclonal,
1:200, Chemicon), human GDNF (goat polyclonal, 1:250, R&D),
and choline acetyl transferase (ChAT, goat polyclonal, 1:200,
Chemicon). After primary antibody incubation, biotinylated
secondary (1:200, Jackson Labs., http://www.jacksonimmuno.
com/) and avidin–biotin method was followed by DAB (Vectors
Laboratories Inc., http://www.vectorlabs.com/) development.
Nickel ammonium sulfate enhancement was used for human
GDNF immunostaining. For double labeling with hNUC,
antibodies against human nestin (mouse monoclonal, 1:200,
Chemicon), glial fibrilly acidic protein (GFAP, rabbit polyclonal
1:2000, Dako, http://www.dako.com/), ED1 (mouse monoclonal,
1:500, Serotec, http://www.ab-direct.com/), Ki67 (mouse mono-
clonal, 1:200, BD Biosciences, http://www.bdbiosciences.com/),
or glutamate transporter GLT1 (rabbit polyclonal 1:200, gift from
Dr. Jeffrey D. Rothstein, Department of Neurology, Johns
Hopkins University School of Medicine) was used. Primary
antibodies were followed by secondary antibodies conjugated to
Cy3 or Alexa Fluor 488 (anti-IgG, 1:1000, Jackson Laboratories).
For retrograde labeling of motor neurons, 2.5% True blue (Sigma-
Aldrich) was injected into hind limb muscles 4 days prior to
sacrifice. All images were optimized by using a fluorescence
microscope or a laser scanning confocal microscope (Nikon,
http://www.nikonusa.com/). To quantify astrocyte activation the
number of GFAP positive cells on both sides of the spinal cord was
counted using Metamorph Imaging software (Universal Imaging
Corporation, http://www.moleculardevices.com), and presented
as a percentage of the total number of counted cells, and
compared in Prizm software (Graphpad software Inc., http://
www.graphpad.com/). To compare microglial activation we
measured the mean intensity of ED1 fluorescence in the ventral
horn. Digital gray scale images were taken at fixed exposure time,
magnification, and background/threshold parameters. The same
size box was placed over the ventral horn region and integrated
optical density of labeling expressed as gray pixel value was
measured using SCION IMAGE software (Scion Co., http://
www.scioncorp.com/). For the stereological analysis, the sections
were prepared at 35 mm thickness, and every 6
th section was
immunostained for hNUC. An unbiased estimate of the
population of transplanted cells was obtained by using the optical
fractionator probe within StereoInvestigator software (MBF bio-
science, http://www.mbfbioscience.com/). This probe was used to
estimate population size by systematically sampling known
fractions within a region of interest. Equipment consisted of
a Zeiss AxioPlan 2 microscope (Carl Zeiss, http://www.zeiss.com/
) with a motorized x-y stage and a microcator for measuring
movements in the z direction. Counts of hNUC positive cells were
performed using a 1006 oil-immersion objective. A grid size
(400 mm6400 mm) was randomly placed on the tissue image
which determined where the counting frames (15 mm615 mm)
were placed. Counting frames were superimposed on the image of
the tissue and all cells stained with hNUC antibody, within the
frame, were counted. Each section was traced and a 3D image was
re-constructed by StereoInvestigator software. We also estimated
Coefficient of Error using the software. Coefficient of Error
represents a measure of the variance of the estimate from
counting; which includes both the biological variation and the
error introduced by the counting method. Coefficient of Error less
that 0.1 indicates that the variance is sufficiently low enough to
accept the estimation as accurate or at least not influenced by
those two variables.
Behavioral testing
Body weight measurements and all behavioral testing began at an
age of 65 days and continued until endpoint. Rats were considered
end-stage (endpoint) when they no longer exhibit reflexes allowing
them to right themselves within 30 seconds. To analyze motor
function in hSOD
G93A rats, the Basso-Beattie-Bresnahan (BBB)
locomotor rating test and a beam walking test were performed
twice a week. Open field locomotor scores were obtained in a small
enclosure using the BBB locomotor rating scale as described
previously [28,29]. Briefly, each rat was allowed to walk around in
a wading pool with a textured floor while we observed hind and
fore limb movements for approximately 3 to 5 minutes. Each hind
limb score was based on the 21 point scoring scale from no
movement (0) to normal locomotion (21). Scoring takes into
account paw rotation, toe clearance, weight support, the frequency
of each, and the amount of movement occurring from each joint.
The beam walking test was used to measure motor coordination
and balance in ALS rats [29]. Briefly, rats were placed individually
on one end of a seven-foot long multi-plane beam and allowed to
run across. These different planes signified different scores based
on hind limb placement while crossing the length of the beam.
Each score was then recorded and summed for each hind limb to
determine that limb’s score. The total score was obtained by
adding both hind limb scores. Cumulative survival statistics of
disease onset was analyzed using the Kaplan-Meier method with
Prizm software. Disease onset was estimated by using the BBB
rating score of 17 or lower [29].
Assessment of neuromuscular junction (NMJs)
innervation
Tibalis anterior muscles were dissected and flash-frozen in
supercooled isopentane. Muscles were sectioned at 20 mm using
a cryostat and placed on glass slides for staining. The sections were
fixed with 4% paraformaldehyde-phosphate buffered saline and
labeled with alpha-bungarotoxin conjugated with fluorescence
marker Alexa Fluor 594 (1:1000, Invitrogen), anti-neurofilament
160 (mouse monoclonal, 1:40, Sigma-Aldrich) and anti-synapto-
physin (rabbit polyclonal, 1:40, Dako) antibodies for 1 hour at
room temperature. After washing with PBS, the sections were
incubated with both anti-mouse and rabbit Alexa Fluor 488-
conjugated secondary antibodies (1:1,000, Jackson Laboratories)
for 1 hour at room temperature. Following washing, the sections
were covered with cover glasses using aqueous mounting medium
Motor Neurons in ALS
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on a fluorescence microscope (Nikon) and Metamorph Imaging
software (Universal Imaging Corporation). For quantitative
analysis, we classified NMJs into three groups based on degree
of innervation of postsynaptic receptor plaques by nerve terminals.
Endplates were scored as ‘‘innervated’’ if there was overlap with
the axon terminal, or ‘‘denervated’’ if the end-plate was not
associated with an axon. Some neuromuscular junctions were
associated with a preterminal axon only, or partial overlap
between endplate and terminal. These were categorized as
‘‘intermediate’’. About 50–60 endplates were exhaustively ana-
lyzed in each muscle from animals of each group. The number of
endplates of each category was presented as a percentage of the
total number of counted NMJs, and compared in Prizm software.
Lumbar motor neuron count
Spinal cord sections (adjacent 5 sections to the injection sites) were
mounted on slides and allowed to dry overnight. The slides were
put through a gradual series of dehydration and re-hydration
solutions, stained with Cresyl violet, differentiated, and cover-
slipped. Light microscopy images of the lumbar spinal cord were
captured bilaterally with a digital camera (SPOT II, Diagnostics
Instruments, http://www.diaginc.com/). A circular area-of in-
terest was positioned over the ventral horn on both sides of the
spinal cord. Area of interest, size, and position were standardized
across sections by choosing a circular circumference that matched
the curvature of the ventral horn. Each Nissl-stained neuron in the
ventral horn with a distinct nucleolus and a darkly stained
cytoplasm was manually traced using Metamorph Imaging
software. Based on a pilot study, using motor neurons immunos-
tained with ChAT or SMI32, a-motor neurons were defined as
having cross-sectional area $700 mm
2. All a-motor neurons were
counted in the selected area of the ventral horn.
GDNF ELISA
hNPC
GDNF and hNPC
WT were bilaterally (120,000 cells in 1 ml, 2
sites per one side) injected in the lumbar spinal cord of a wild-type
female rat as described above. Four regions (1 cm each) from both
the transplanted and outside the transplant were dissected and
flash-frozen in supercooled isopentane. The tissues were then
suspended in 1 ml of lysis buffer [26], incubated for 15 min on ice,
centrifuged for 15 min at 10,000 g at 4uC and stored at 280uC.
Protein concentration was determined by a detergent-compatible
modified Bradford assay (Bio-Rad, http://www.bio-rad.com/).
The concentrations of GDNF protein were measured by ELISA as
described above.
RESULTS
hNPC can be modified to release GDNF and
ameliorate early motor neuron loss in hSOD
G93A rats
hNPC were isolated from the cortex of 15 week old human fetal
tissue under the guidelines set out by NIH for collection of such
tissues, and local IRB approval. Following expansion as spherical
neurospheres [24], they were infected with a lentiviral construct
encoding GDNF under the control of phosphoglycerol kinase (PGK)
promoter (Figure 1B). Approximately 87% of hNPC
GDNF cells
expressed the GDNF protein based on immunocytochemistry
(Figure 1C–E) which was released into the media at a rate of
618 pg/hr/million cells (Figure 1F). Non-infected hNPC (wild-type
hNPC, hNPC
WT) did not release detectable amounts of GDNF.
Release of GDNF from the cells was maintained following 1 and 7
days differentiation into neurons and astrocytes (Figure 1G).
We next wanted to assess whether hNPC
GDNF could affect
motor neuron survival following transplantation into the spinal
cord of SOD1
G93A rats. We have previously shown that SOD1
G93A
founder rat colonies show disease onset at approximately either 105
days (early onset) or 160 days (late onset) in addition to a gender
specific effect with males showing an earlier onset than females
[29]. Although we did not have any way to predict which onset type
they would have prior to transplantation, we only used female
animals to reduce sex based variation. hNPC
GDNF (182,000 cells/
mL62 mL64 unilateral sites in L1/L2) were transplanted into the
lumbar spinal cord of SOD1
G93A rats (n=6 females for each group)
at 70 days of age (Figure 2A). Although a full behavioral assessment
was not performed on this group of animals,none showed anyovert
signs of limb paralysis at 6 weeks after grafting (112 days) suggesting
that this would have been a late onset cohort. Animals were
sacrificed at either 2 or 6 weeks post transplantation. Three rats in
the 2 week survival group and 4 rats in the 6 week survival group
were found to contain human cells based on the specific human
nuclear antigen (hNUC). Surviving cells were well targeted and had
migrated out unilaterally into degenerating regions of the ventral
horn in all of these animals (Figure 2B). The transplants spread
anteriorally and posteriorally up to 7.2 mm (4.863.9 mm at 2
weeks and 4.460.9 mm at 6 weeks post transplantation; mean6-
SEM) from the injection sites (Figure 2G). There were no adverse
effects in any of the animals and no sign of excessive cell growth
indicative of tumor formation. In one of the hNPC
GDNF treated
animals we also performed a stereological analysis to count the total
number of hNUC positive cells at 6 weeks post transplantation.
Approximately 1,456,000 cells were transplanted and 1,629,750
cells were estimated to be within the spinal cord using stereological
counting methods. As clearly shown in Figure 2G, the transplanted
cells migrated out within one side of the lumbar spinal cord in this
rat and did not cross the midline.
We next checked GDNF release from these cells using
immunocytochemistry and found that the location of hNUC
positive cells correlated exactly with the release of GDNF into the
surrounding area (Figure 2C). In regions of GDNF delivery many
host motor neurons were labeled with GDNF suggesting active
uptake of the protein into surviving motor neurons (Figure 2D).
We also determined GDNF released from the transplanted cells in
the spinal cord using ELISA. At 6 weeks following transplantation
of 3 more animals (480,000 cells total), 1 cm regions from both
inside and outside the transplant were dissected, homogenized,
and then processed for GDNF ELISA. Significant amounts of
GDNF (up to 820 pg/mg tissue protein) were detected in the
region of the spinal cord with the transplants, but not outside
(Figure 2H). Animals transplanted with wild type hNPC did not
show any detectable GDNF release.
In order to establish whether GDNF secreting hNPC could
ameliorate motor neuron loss, we counted the number of Nissl
stained or choline acetyltransferase (ChAT) positive cells both within
the region of the transplant and outside the region of the transplant.
There wasverylittlelossat 2 weeks post grafting (94 dayold animals)
in either the transplanted or non transplanted side when compared
to wild type animals (Figure 3E) suggesting that motor neuron
degeneration had not yet reached significant levels in this late onset
cohort of animals. However, by 6 weeks post grafting (112 day old
animals) there was a significant 70% reduction in motor neuron cell
numberinthenon-transplantedsideofthe SOD1
G93Aratwhichwas
almost completely prevented within chimeric regions of the spinal
cord (Figure 3E, F). Outside of these chimeric spinal cord regions
there was no protection of motor neurons (Figure 3E, F). Thus, even
within the same animal, hNPC
GDNF can provide local protection of
motor neurons from cell death.
Motor Neurons in ALS
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GDNF in the spinal cord of the SOD1
G93A rats. (A) Rats were transplanted with hNPC
at day 70 and sacrificed at either 2 or 6 weeks post transplantation. (B) Staining with the human specific marker (hNUC) showed unilateral survival of
cells in the ventral grey and white matter. (C) Surviving cells release GDNF. (D) Some endogenous rat motor neurons were decorated with GDNF. (E)
ChAT and (F) Nissl staining showed increased motor neuron number around the transplant site. (G) There was widespread distribution of hNPC in the
lumbar region of the spinal cords 6 weeks after transplantation. (H) GDNF expression was detected only in the area of the cell transplant. Scale bars:
1m mi nF; 100 mmi nD.
doi:10.1371/journal.pone.0000689.g002
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GDNF express nestin but not GFAP or
GLT1 and do not affect host reactive astrocytes
It was possible that the hNPC
GDNF were generating glial cells
that provided additional protection to the dying motor neurons
[19]. In the 6 week transplant group, human cells within the
transplant core were found to remain GFAP
+ (Figure 4A, G) and
Nestin
+ (Figure 4D, H). However, following migration, the
majority of cells (.95%) retained nestin expression (Fig.4E, H)
but down regulated GFAP (,10%) (Figure 4B, G). Other
labeling showed that these migrating cells did not express two
other astrocyte markers vimentin or S100, suggesting that they
were not reactive astrocytes. They were also negative for
neuronal markers such as TuJ1 (data not shown). Glutamate
transport by glial cells may protect motor neurons in rodent
models of familial ALS [33]. However, the hNPC
GDNF did not
express GLT1 and furthermore we found that host cells
surrounding the dying motor neurons expressed high levels of
GLT1 in non transplanted and transplanted regions of the spinal
cord (Figure S1). This is in contrast to other studies that have
shown down regulation of this transporter in the same model [5].
Together, this data suggests that the hNPC that migrated along
side the dying motor neurons were not reactive GFAP expressing
astrocytes with glutamate transporters, but rather immature
nestin positive progenitors.
Activation of host glial cells is one hallmark of ALS, and
increases with disease progression in the SOD1
G93A rat which
may be either protective or contribute to motor neuron death
[16]. The number of host GFAP reactive astrocytes (not hNUC
labeled) in the grafted vs. non-grafted side at 6 weeks post
transplantation was the same (Figure 5C). This suggested that the
protective effects of hNPC
GDNF were not mediated through
a modulation of host reactive astrogliosis. We also determined the
levels of microglia activation by using immunostaining for reactive
microglial marker ED1. There was no difference in the level of
microglia activation within regions of motor neuron protection
away from the core of the transplant (Figure 5E, F). However,
there were reactive microglia in the transplant core (Figure 5G)
which may suggest a low grade rejection phenomenon at high cell
density as we have reported previously in cyclosporine treated
animals [34]. This may also explain why some rats had no
surviving transplants.
Figure 3. Motor neurons are protected by GDNF secreting hNPC transplants in the spinal cord of SOD1
G93A rats. The number of motor neurons
was higher in hNPC-transplanted (chimeric) side (B, D) compared to the contralateral non-grafted (non-chimeric) hemisphere (A, C). Cell number
reduced by 70% at 6 weeks post grafting in sham treated SOD1
G93A rats (E). There was almost complete protection of motor neuron loss within
chimeric (transplant) regions of the spinal cord. Outside of these transplant (non-chimeric) regions motor neuron numbers dropped to less than 70%.
The broken line indicates the number of motor neurons in wild-type rats. (F) The ratio of motor neuron numbers compared to the contralateral side.
*: P,0.05 vs. 2 wks and 6 wks outside groups. Scale bar: 100 mmi nD.
doi:10.1371/journal.pone.0000689.g003
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GDNF transplants do not lead to a reduction in
ipsilateral limb paralysis in SOD1
G93A rats showing
early onset
We next wanted to assess whether the hNPC
GDNF transplants
resulted in any positive or negative effects on limb function in the
SOD1
G93A rat, and dissociate the effects of GDNF release from
the effects of the cells themselves. For these studies a second cohort
of female SOD1
G93A rats were unilaterally transplanted at 70 days
with either hNPC
WT (n=12), hNPC
GDNF (n=12) or just received
vehicle saline infusions (control; n=6). In contrast to the first
cohort of animals, distinct hind limb changes were noticed at early
time points suggesting an early disease onset in this group.
However, there was no significant difference in hind limb disease
onset between the transplanted side and the non-transplanted side
in any animal (Figure 6A, B). We also tested individual limb
function using the Basso-Beattie-Bresnahan (BBB) rating test
where both groups of animals showed similar disease progression
up to 115 days of age (Figure 6C, D). Finally, we used a beam
walking test to measure motor coordination and balance after
onset and again found no effect of the transplant on this behavioral
task (data not shown). Together, this data shows that while there
was no detrimental effect of the transplant on motor function,
there was no apparent benefit either. Furthermore, it was also
clear that this cohort showed an aggressive and early onset of
disease and rapid progression when compared to the cohort used
Figure 4. Migrating hNPC
GDNF express nestin but not GFAP. Confocal stacked images through sections show hNPC were GFAP positive within the
core of the transplant (A, C, G). However, away from the site of the transplant GFAP expression was lost (B, G). Continual nestin expression was
observed in both the transplant core and the region of migrating cells (D, E, F, H). Scale bars: 20 mmi nA–E;5mmi nF.
doi:10.1371/journal.pone.0000689.g004
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hNPC
WT group and 4 from the hNPC
GDNF group were at disease
end stage before the 6-week post graft date had been reached.
GDNF released by hNPC can maintain healthy
cholinergic motor neurons within chimeric spinal
regions until disease end point, but have no effect
on loss of muscle innervation in SOD1
G93A rats
The animals used for behavioral testing above were sacrificed at
either 6 weeks or disease end point, whichever came first. Six out of
the 12 animals with hNPC
WT had surviving transplants while 9 out
of 12 animals with hNPC
GDNF had surviving transplants. The
average number of surviving motor neurons in the non-transplanted
side was approximately 2.560.7 per section (compared to 6.362.2
in the first cohort of animals) further suggesting a more aggressive
disease progression in this group. However, there was a highly
significant 2.5 fold increase in motor neuron survival within the
hNPC
GDNF group when compared with the non grafted side
(P,0.01; Figure 7B, C). A number of animals (n=4) in the
hNPC
GDNF group reached disease end stage during the 6 week
period and were analyzed separately. Even at this time point the
number of motor neurons remained significantly higher within
chimeric regions of the spinal cord when compared to the
contralateral side (5.561.5 in the transplanted and 1.360.5 in the
non-transplanted side; Figure 7B, C; P,0.05). Interestingly, there
was no significant difference in the number of motor neurons within
chimeric regions of the hNPC
WT group and the non-transplanted
side (2.160.7 in the transplant side and 3.161.3 in the non-
transplantside,Figure7C)showingthatGNDFreleasefromthecells
is responsible for the increased motor neuron survival.
Figure 5. Glial cell activation is not changed following hNPC
GDNF transplantation in the spinal cord of SOD1
G93A rats. Photomicrographs of the
non-transplanted (A) and the hNPC-transplanted (B) indicate no change in number of GFAP positive reactive astrocytes in the ventral root of the
spinal cord (C). Similarly, there was no difference in the level of microglia activation within regions of motor neuron protection (D–F). However,
a detailed analysis using higher magnification (G) revealed microglia activation in the transplant core (the left side of a broken line indicating the
border between the transplanted core). Scale bars: 50 mmi nA, B, D, E;2 0mmi nG.
doi:10.1371/journal.pone.0000689.g005
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each animal for both ChAT and ubiquitin, one marker of
degenerating motor neurons in this model [19]. Most of the large
surviving ChAT
+ motor neurons within chimeric regions of the
transplanted spinal cord did not express ubiqutin (P,0.01;
Figure 7A, D). Both the transplanted and non transplanted side
also contained a number of ChAT
+/ubiquitin
+ (early degenerating
motor neuron) and ChAT
2/ubiquitin
+ (late degenerating motor
neuron). Although there was a trend for more of these in the non
transplanted side the differences were not significant (P,0.07).
Clearly there is death of cholinergic neurons even in the presence of
GDNF, but those motor neurons that are protected are not
undergoing degeneration based on ubiquitin staining. Together,
these data show that secreted GDNF from hNPC was able to
maintaincholinergicmotorneurons upuntil diseaseend point inthis
model of familial ALS. In fact, the degree of survival was similar to
the number of motor neurons seen at earlier pre symptomatic stages
shown in the first cohort of animals (6.362.2). Finally, we also
assessed whetherGDNF may have reduced the expression of human
mutant SOD1 protein in surviving motor neurons. It was clear that
all remaining cholinergic motor neurons protected by GDNF
continued to express human mutant SOD1 (data not shown).
Given the extent of protection by GDNF, we were surprised that
this did not result in recovery of some limb function. Previous studies
using the pmn mouse model [35] and the Bax-deficient mice crossed
with mice expressing mutant SOD1
G93A [36] have shown that
GDNF can protect motor neurons which are no longer connected to
the muscle. We therefore analyzed neuromuscular junctions (NMJs)
in the animals that had shown increased motor neuron survival
within the spinal cord (Figure 8). Using a combination of hNPC
transplants and intramuscular injection of retrograde tracer True
Blue, we first confirmed that the region of muscle analyzed received
projections from the chimeric spinal cordregion (see Figure S2). The
level of innervation in hind limb muscles (tibialis anterior) was
estimated by using double staining for axons and motor endplates.
We classified NMJs into three groups (innervated, denervated, and
intermediate) based on degree of innervation of post synaptic
receptorplaquesbynerveterminals.In thepre-symptomaticanimals
upto80daysold,over80%ofendplateswereinnervated(Figure8A,
D, G, J). The number of denervated endplates was gradually
increased by the mid-stage (Figure 8B, E, H, J), and all endplates
were denervated at end-stage (Figure 8C, F, I, J). Interestingly, we
found that there was no significant effect of hNPC
GDNF on the
innervation of neuromuscular junctions at the hind limb muscle in
the 4 animals showing increased numbers of healthy cholinergic
motor neurons in the spinal cord (Figure 8K). We conclude that
while hNPC releasing GDNF were able to protect motor neurons,
theywere no longer connected to the muscleand thus not improving
ipsilateral limb function in this rat model of FALS.
DISCUSSION
Our data show that transplantation of hNPC releasing GDNF can
have dramatic effects on motor neuron survival in the SOD1
G93A
rat model of familial ALS. At early, pre symptomatic stages of the
Figure 6. Disease onset and ipsilateral limb function was not affected by hNPC transplants in SOD1
G93A rats. Kaplan-Meier curves of disease onset
in the animals with hNPC
GDNF (A) or hNPC
WT (B) transplants. Basso-Beattie-Bresnahan (BBB) locomotor rating scores (C, D) showed that a significant
difference was not observed in between the transplanted side and the non transplanted side in any group.
doi:10.1371/journal.pone.0000689.g006
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neurons which otherwise would have reduced to only 30% of
normal values (Figure 3). Even at symptomatic disease end stage
GDNF was able to maintain over 30% of the motor neurons,
a level which should be sufficient to prevent symptoms. However,
muscle innervation was not maintained in these same animals and
no changes in limb function were observed.
GDNF release from hNPC increases motor neuron
survival
Direct gene therapy to the spinal cord using the same lenti-GDNF
construct described in the current study has previously been
attempted with no protective effect on lumbar motor neurons in
the mutant SOD1 mouse, even though high levels of GDNF
secretion was achieved [14]. Direct gene therapy involves the
infection of motor neurons that are undergoing degeneration and
it is possible that this approach induces a high level of stress that
reduces any possible neuroprotective effects [37]. Since in the
current ex vivo gene therapy approach used hNPC to deliver the
protein, host motor neurons did not need to be exposed to
lentivirus which may have increased the chance of neuroprotec-
tion. Furthermore, other factors secreted by the hNPC may have
worked with GDNF to improve survival.
There are a number of ways in which GDNF produced by
hNPC may modulate motor neuron survival. In ALS, glial
activation has been described in the spinal cord of patients [38]
and SOD1 mice [4]. Assuming that reactive gliosis occurs in
response to motor neuron death, it was possible that rescue of
a substantial fraction of neurons would have reduced the extent of
the reactive gliosis on the grafted side. However, we found that
astrogliosis was not reduced and we observed highly reactive
microglia throughout the spinal cord in both sham treated and
transplanted animals at end stage. Thus, the protective effects of
GDNF were not mediated through a modulation of host reactive
astrogliosis, and GDNF induced the survival of motor neurons
expressing mutant SOD1 protein within a highly reactive
environment. We were surprised to find that most cholinergic
motor neurons protected by GDNF had not even started to
express early markers of cell death such as ubiquitin. We suggest
Figure7.GDNFreleasedfromthehNPCiscriticalfor motorneuronsurvivalinthismodel.(A)EventhoughanumberofanimalsinthehNPC
GDNFgroup
reachedendstage, the numberofmotorneurons was higher inhNPC-transplantedsidecomparedtothecontralateralnon-graftedhemisphere.Surviving
hNPC were found in the adjacent section of the transplanted side, but not in the contralateral side. We also double labeled sections throughout chimeric
regions of each animal for both ChAT (red) and ubiquitin (UB; green), While the non transplanted side contained many ChAT
+/ubiquitin
+ (early
degenerating motor neuron; indicated by arrows) and ChAT
2/ubiquitin
+ (late degenerating motor neuron; a star), most of the surviving ChAT
+ motor
neurons within chimieric regions of the transplanted spinal cord did not express ubiqutin (designated by arrow heads). (B) Motor neuron counts showed
that there was a significant increase in motor neuron survival at both early and late time points within chimeric spinal cord regions rich in GDNF (n=9 for
total, 4 for mid stage and 5 for end stage). (C) While wild type hNPC not releasing GDNF did not affect motor neuron cell death in this model, there was
approximately 2.5 fold increase compared to the non-grafted side in motor neuron survival in the hNPC
GDNF group. *: P,0.05 vs. hNPC
WT.( D) Cell
countingusingsectionsdoublelabeledforbothChAT andubiquitin revealedthatsecretedGDNFfromthehNPCwas abletomaintainhealthycholinergic
motor neurons up until disease end point in this model of familial ALS. *: P,0.05 vs. cell (-). Scale bar: 50 mm.
doi:10.1371/journal.pone.0000689.g007
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hNPC, activates cell protection pathways within host motor
neurons that may be linked to anti-apoptotic proteins [39,40].
hNPC alone have no effect on motor neuron survival
Our studies were prompted by elegant data from chimeric mice
showing that mutant SOD1-overexpressing neurons surrounded
by normal glia remained relatively intact, whereas normal neurons
surrounded by mutant SOD1-overexpressing glia showed signs of
damage [17–19]. We initially hypothesized that transplanted
hNPC not releasing GDNF would give rise to fresh glial cells, and
that the chimeric regions would show decreased motor neuron
death. However, wild type hNPC had no effect on motor neuron
survival (Figure 7A). This could be due to a number of factors.
First, we did not see any GFAP expression in cells that had
migrated into regions of motor neuron degeneration which instead
retained the progenitor cell marker nestin. This suggests lack of
maturation or slow development of the human cells which we have
seen previously following transplantation of hNPC into the
striatum [24]. There is also a wide heterogeneity of astrocyte
types which is affected by strain [41] and region from which the
progenitor cells were isolated [42]. As mentioned below, other
groups have shown hNPC derived from the spinal cord can
produce GDNF [43] and in our own studies hNPC derived from
the mesencephalon also produce GDNF (Kim and Svendsen,
unpublished observations). Thus, perhaps astrocytes from corti-
cally derived hNPC are not able to support spinal cord motor
neurons. Astrocytes are essential partners of motor neurons, not
only providing them with trophic support, but also mediating
rapid recovery of synaptic glutamate through the action of the glial
glutamate transporter GLT1 [44]. Interestingly, hSOD1
G93A mice
heterozygous for GLT1 develop earlier-onset disease, while drugs
that increase GLT1 activity extend survival [45]. While we did see
expression of EAAT2 (human GLT1 homologue) in hNPC in vitro,
both the core and surrounding regions of the transplant were
totally negative for this transporter based on immunocytochem-
istry (Figure S1) suggesting down regulation in vivo. However, we
were surprised to find that even at end stage there was expression
of the GLT1 transporter using immunocytochemistry in the
ventral horn surrounding the dying motor neurons, both inside
and outside of the transplant region. This is in direct contrast to
a previous report in the same rat model [5] although other groups
have also failed to see reduced GLT1 expression in mouse models
of ALS [46]. While there may be technical differences with regard
to antibody sensitivity, we would confirm this later study, and
suggest that in this model expression of at least low levels of GLT1
is not sufficient to prevent motor neuron death. It would however
be very interesting to express higher levels of GLT1 and see if this
has protective effects on these motor neurons. Together, our data
show that while hNPC can survive and integrate they do not
produce mature astrocytes that can prevent the death of motor
neurons.
Other recent studies have shown more positive effects on limb
function when human neural progenitor cell cultures derived from
the developing spinal cord have been transplanted into the
SOD1
G93A rat [43]. While the cells appeared to extend the onset
and endpoint of disease to a small degree, there was no control for
possible gender influences (male vs. female ratio was not given) or
drift in the colonies that are prominent with this animal model
[29,47]. This study also suggested an increased survival of motor
neurons in chimeric regions in a small subset of three animals per
group, even in the absence of maturation into GFAP positive
astrocytes [43]. Regional specificity of neural stem cells has been
shown previously [48–50] and therefore it is possible that spinal
cord derived neural stem cells have different properties following
transplantation. Interestingly, spinal cord neural stem cells
Figure 8. Neuromuscular junction innervation following hNPC transplantation. Axons were identified with synaptophysin and neurofilament
(SYN+NF), motor endplates were identified with a-bungarotoxin (a-BTX). (A, D, G) In pre-symptomatic animals (80 days old), most endplates were
innervated (yellow). (B, E, H) The number of denervated (an arrow head) endplates increased at the mid-stage (110 days old), although a few were still
innervated (a white arrow). (C, F, I) All endplates were denervated at end-stage. (J) In the pre-symptomatic animals (40, 60, and 80 days old), over 80%
of endplates were innervated. The number of denervated endplates was gradually increased by the mid-stage (100 days old), and most of endplates
were denervated at end-stage. (K) Detailed endplate counts showed that there was no significant effect of hNPC
GDNF on the innervation of
neuromuscular junctions in the hindlimb muscle of animals showing increased numbers of motor neurons in the spinal cord. Scale bar: 20 mm.
doi:10.1371/journal.pone.0000689.g008
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neurons after grafting [43] in contrast to more extensively
passaged cortical derived neural progenitor cells used in the
current study which do not produce GDNF or neurons after
grafting [27,28]. Thus, GDNF may have been responsible for the
effects on motor neuron survival in this study. While a direct
comparison between cortical and spinal cord derived neural
progenitor cells within the same experiment would be interesting,
from a practical point of view human neural progenitor cells
derived from the spinal cord are more difficult to expand than
those from the cortex [51] and may therefore be less useful for
future clinical studies. More modest effects on function with little
detailed analysis of motor neuron survival have been seen when
mouse sertoli cells [52] or hNT neurons [53] derived from
a human teratocarcinoma line were transplanted into mouse
models of FALS. In both cases the cells produced GDNF which
again may have contributed to the effects.
Healthy surviving motor neurons do not maintain
contact with muscle fibers
Connection to the muscle at the neuromuscular junction is lost in
ALS mouse models long before motor neuron degeneration or
death and the initiation of symptoms, leading to the hypothesis
that ALS may be a ‘‘dying back’’ axonopathy [54,55]. A similar
phenomenon has been reported in previous experiments where
GDNF could protect motor neurons that had retracted from the
muscle in the pmn mouse model [35]. Furthermore, deletion of the
proapoptotic protein, Bax, has been shown to completely protect
motor neurons in the ALS mouse model that have no distal
connections to the muscle [51]. To address this question we
analyzed motor endplates which showed a similar, but less rapid
decline in number to that found in the mouse model. We found
that motor neurons surviving in the spinal cord due to GDNF
delivered by the hNPC did not reduce the number of denervated
muscle end plates. Our results suggest that protection of both cell
bodies and nerve terminals in the muscle may be required for
functional limb improvements in this model of familial ALS, and
provides further data in the rat supporting previous mouse studies
showing that the survival of the motor neuron can be independent of
muscle innervation [51]. An interesting recent study showed that in
a viral model of motor neuron degeneration, axonal outgrowth and
attachment to the muscle could be achieved from transplanted
motor neurons by using GDNF secreting cells implanted into the
sciatic nerve [56] and that insulin-like growth factor 1 (IGF1) may
have specific effects on motor neuron fiber outgrowth [57]. We feel
that these types of combinatorial approaches of cells and different
growth factors may improve muscle connection and lead to potential
improvements in limb function.
Potential for ameliorating motor neuron loss in ALS
Before considering using stem cells for transplantation into patients
it is essential to show that there is minimal risk of tumor formation,
survival within a diseased environment and low levels of adverse
functional effects. Neural tissues derived from mouse ES cells can
form teratomas in the brain [58]. Furthermore, a recent report
showed that the grafts derived from human ES cells exhibited
expansion cores of undifferentiated mitotic neuroepithelial cells
[59]. Fetal-derived hNPC described in the current studies divide
for only a limited time following transplantation into the striatum
[34] and have not been shown to form tumors in a large number
of animal studies. In the current work we confirm that there was
no sign of mitotic cells or tumor formation within the grafted area
of SOD
G93A rats. Furthermore, there were no adverse effects on
function, even when high numbers of cells were found to survive.
It is remarkable that given the severely degenerative xenograft
environment, the human progenitor cells were still able to survive,
integrate and release GDNF that had a protective effect on motor
neurons in this model of familial ALS. Given the major issues for
delivering this and other growth factors to specific regions of the
spinal cord and brain we feel this is an important new approach to
drug delivery in ALS patients that may also be applicable in other
disorders [60]. While we conclude that hNPC secreting GDNF
may represent a viable source of cells for protecting dying motor
neurons, further animal studies are clearly needed to slow the loss
of muscle innervation and thus increase the chances of functional
recovery following transplantation.
SUPPORTING INFORMATION
Figure S1 Immunostaning of reactive microglia marker ED1 and
glutamate transporter GLT1. The grafted hNPC do not express
GLT1 in both the surrounding (A) and core (B) regions of the hNPC
transplant. (C) A detailed analysis using higher magnification
revealed microglia activation in the transplant core (the left side of
a broken line indicating the border between the transplanted core).
Scale bars: 100 mmi nA ;5 0mmi nB ;2 0mmi nC .
Found at: doi:10.1371/journal.pone.0000689.g001 (1.94 MB TIF)
Figure S2 The correlation with the tracer labeled motor
neurons and hNUC staining. hNPC were unilaterally transplanted
into the lumbar spinal cord of wild type rats. After surgery,
a retrograde tracer True Blue (2.5%) was injected into the same
side as the hNPC transplants of the tibialis anterior muscle. Four
days after transplantation, the spinal cord was collected and
checked for true blue positive neurons in the lumbar spinal cord
(A). Furthermore, the adjacent section was immunostained with
hNUC antibody (B). Scale bars: 100 mm.
Found at: doi:10.1371/journal.pone.0000689.g002 (1.74 MB JPG)
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